MétaCan
Menu
Back to cohort

Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.

2018· article· en· W2891105830 on OpenAlexaff
Luca Malorni, Chiara Biagioni, Amelia McCartney, Gaia Schiavon, Mattias Bergqvist, Matteo Benelli, Ilenia Migliaccio, Laura Biganzoli, Martina Bonechi, Giulia Boccalini, Marta Pestrin, Francesca Galardi, Francesca De Luca, Martine Piccart, William J. Gradishar, Stephen Chia, Angelo Di Leo

Bibliographic record

VenueJournal of Clinical Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsMedicineInternal medicineFulvestrantCancerClinical endpointRandomizationBreast cancerOncologyProgression-free survivalExemestaneGastroenterologyRandomized controlled trialGynecologyChemotherapyAromataseEstrogen receptor

Abstract

fetched live from OpenAlex

12031 Background: TK1 plays a critical role in DNA synthesis and cell proliferation. The DiviTum assay measures serum TK1 activity (sTKa), reflecting cancer cell proliferation. Recent studies suggest this assay may provide real time prognostic information in ABC. However, its role in HR+ ABC needs further validation. Methods: EFECT (n = 693) was a double-blind, randomized trial of fulvestrant 250mg versus exemestane after progression on nonsteroidal aromatase inhibitor therapy for ABC. 58% of pts had received > 1 prior ET for ABC. sTKa was retrospectively assessed with DiviTum on serum samples from pts in the EFECT cohort. Samples were collected before start of ET (T0), after 3 (T3) and 6 (T6) months of ET, and at disease progression (PD). Pts were categorized as High/Low sTKa at T0 based on the median value. On-treatment sTKa changes were calculated from T0 to the next available time-point within 3 months from randomization (T3, or PD for those pts with early progression - ePD), accounting for a coefficient of variation of 10%, and defined as follows: Drop (T3 or ePD < T0); Increase (T3 or ePD > T0); No change (T3 or ePD = T0). Analyses were conducted regardless of study arms. Results: All available samples were successfully tested for sTKa (586 samples from 244 consenting pts). Median sTKa at T0 (n = 227), T3 (n = 135), T6 (n = 80) and PD (n = 137) was 97, 57, 57.5 and 132 Du/L, respectively. Median time to progression (mTTP) for pts with Low T0 sTKa (n = 111) was 5.03 months (m) (95% CI 3.91-5.89) vs 2.57 (95% CI 2.04-3.52) for pts with High T0 sTKa (n = 110) (p < 0.001). On-treatment sTKa changes from T0 were analysed in 159 pts (T3 = 116; ePD = 43). mTTP in pts with TK1 Drop (n = 53) was 5.4 m (95% CI 3.7-7.7) vs 3.4 (95% CI 2.1-4.1) in pts with Increase (n = 68) (p < 0.018). mTTP in pts with No change (n = 38) was similar to those with Drop. After adjustment for major prognostic factors, sTKa remained an independent marker. Conclusions: sTKa is a potential circulating prognostic marker in pts with ABC treated with ET, and may represent a tool for upfront identification of ET-resistant pts, and non-invasive monitoring of response to ET. Independent validation of these results is warranted.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.594
Threshold uncertainty score0.609

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.034
GPT teacher head0.404
Teacher spread0.370 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicAdvanced Breast Cancer TherapiesFrench-language works237,207